3 terminated, 2 active not recruiting, 2 completed, 1 recruiting. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Terminated 3, Active not recruiting 2, Completed 2, Recruiting 1 |
Follow Post-essential Thrombocythemia Myelofibrosis: new trials by email Literature Review of Post-essential Thrombocythemia Myelofibrosis trials Research Report on Post-essential Thrombocythemia Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) Bomedemstat - Thrombocythemia, Essential, Primary Myelofibrosis | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 400 | 2024-05-23 | 2026-04-02 |
| Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) Pelabresib, Ruxolitinib, Placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 430 | 2021-04-09 | 2026-07-17 |
| A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) Momelotinib, Placebo to match danazol, Danazol - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Completed | Sierra Oncology LLC - a GSK company | 195 | 2020-02-07 | 2023-11-01 |
| A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib FEDRATINIB - Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 3 | Terminated | Celgene | 38 | 2019-03-27 | 2024-12-12 |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Pacritinib, Physician's Choice medications - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Active not recruiting | Swedish Orphan Biovitrum | 407 | 2017-06-26 | 2026-04-30 |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia Pacritinib, Best Available Therapy - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Terminated | CTI BioPharma | 311 | 2014-02-01 | 2021-11-18 |
| Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis Momelotinib, Ruxolitinib, Placebo to match momelotinib - Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 3 | Completed | Sierra Oncology LLC - a GSK company | 432 | 2013-12-06 | 2023-05-12 |
| Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Pacritinib, Best Available Therapy - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Terminated | CTI BioPharma | 327 | 2013-01-01 | 2020-09-29 |
Primary Myelofibrosis (8) · Anemia (4) · Bone Marrow Diseases (4) · Hematologic Diseases (4) · Myeloproliferative Disorders (4) · Polycythemia Vera (3) · Splenomegaly (3) · Thrombocythemia, Essential (3) · Hemorrhagic Disorders (2) · Thrombocytopenia (2) · Blood Platelet Disorders (1)
Hemic and Lymphatic Diseases (8) · Bone Marrow Diseases (4) · Hematologic Diseases (4) · Myeloproliferative Disorders (4) · Blood Coagulation Disorders (3) · Blood Platelet Disorders (3) · Bone Marrow Neoplasms (3) · Hematologic Neoplasms (3) · Hypertrophy (3) · Neoplasms (3) · Neoplasms by Site (3) · Pathological Conditions, Anatomical (3) · Pathological Conditions, Signs and Symptoms (3) · Thrombocytosis (3) · Cytopenia (2)
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (3) · ruxolitinib (3) · Danazol (2) · N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide (2) · Adrenal Cortex Hormones (1) · Hydroxyurea (1) · bomedemstat (1) · fedratinib (1)
CTI BioPharma (2) · Sierra Oncology LLC - a GSK company (2) · Celgene (1) · Merck Sharp & Dohme LLC (1) · Novartis Pharmaceuticals (1) · Swedish Orphan Biovitrum (1)
United States (8) · Australia (7) · United Kingdom (7) · Canada (6) · Czechia (6) · France (6) · Hungary (6) · Belgium (5) · Germany (5) · Italy (5) · Israel (4) · Netherlands (4) · New Zealand (4) · Poland (4) · South Korea (4)
Simran Singh (2) · Beth Ziemba (1) · Ruben Mesa (1) · Srdan Verstovsek, M.D., Ph.D. (1)
PMID 42316774, PMID 33275766, PMID 37042865, PMID 39516087, PMID 40535755, PMID 41958363, PMID 42452788, PMID 33232476, PMID 34551507, PMID 35950489, PMID 36709073, PMID 37517413, PMID 38501751, PMID 38838026, PMID 39400386, PMID 40065169, PMID 40691344
2023 (2), 2018 (1)